SUMMARY Plasma progesterone was raised in 36 of 50 (72%) men with liver disease compared with 20 healthy male control subjects. Plasma progesterone was significantly higher in men with non-alcoholic cirrhosis with gynaecomastia than those without, but no similar relationship was found in men with alcoholic fatty change and alcoholic cirrhosis. Hyperprolactinaemia was found in 14% of men with liver disease but levels were unrelated to the presence of gynaecomastia. Increased circulating levels of progesterone and prolactin alone do not explain the development of gynaecomastia in patients with liver disease, but progesterone may be an additional factor acting in association with the known disturbances of other sex steroids.
Feminisation commonly occurs in men with liver disease, but the underlying pathophysiological mechanisms are not clearly understood.' Abnormalities of circulating levels of androgens, oestrogens, sex hormone binding globulin, and prolactin occur in liver disease,1-7 but these endocrine disturbances relate inconsistently to the clinical findings, particularly to the presence of gynaecomastia.
Although progesterone is required for optimal mammary growth and lactation,8 and several reports have implicated progesterone as a factor in the production of gynaecomastia,9-" plasma progesterone concentrations have not been reported in men with liver disease. Hyperprolactinaemia has been associated with drug-induced gynaecomastiat2 and occurs in some patients with liver disease,7 12-14 although its importance in the production of gynaecomastia in this condition is in doubt.
To clarify these issues we have measured plasma progesterone and serum prolactin in 50 men with liver disease and related the endocrine findings to the aetiology and severity of the liver disease and to the presence of gynaecomastia. than in those without gynaecomastia (Fig. 1) , although there was no relation between progesterone concentration and gynaecomastia in the subgroups of patients with alcoholic liver disease. Serum prolactin concentration was raised (>360 mU/I) in seven of 49 patients (14%) with liver disease (Fig. 2) 6 An alternative explanation for the failure to find a clear-cut relation between plasma progesterone concentration and the clinical features of feminisation is that the increase in total plasma progesterone may not reflect a parallel change in free hormone concentration. Clearly, direct estimation of free plasma progesterone is needed to determine the contribution, if any, of binding protein abnormalities to the raised total plasma progesterone concentration in men with liver disease.
Our finding of raised progesterone concentration in men with alcoholic fatty change in addition to men with cirrhosis suggests that raised plasma progesterone concentrations are not clearly related to the severity of the liver disease. This is supported by our failure to find a correlation between serum albumin concentration (an indicator of the severity of chronic liver disease) and plasma progesterone concentration.
Spironolactone causes gynaecomastia and produces changes in circulating levels of sex steroids similar to those found in liver diseasell 17 18 -that is, increase in the plasma oestrogen-androgen ratioincluding raised plasma progesterone and its metabolite 17u-hydroxyprogesterone. The increase in plasma progesterone in the present study could not, however, be attributed to administration of this drug, although it does suggest that the gynaecomastia of liver disease and that due to spironolactone may have common underlying mechanisms.
Serum prolactin concentration was raised in 14% of men with liver disease, a value similar to most reported series,3 7 although Wernze and Schmitz '4 found hyperprolactinaemia in 39% of 75 cirrhotic patients. The failure to find any relation between serum prolactin and the presence of gynaecomastia is in accordance with most earlier studies,7 12 14 and might be expected, as the gynaecomastia of liver cirrhosis is not associated with galactorrhea.
Although increased plasma progesterone concentration and to a much lesser extent hyperprolactinaemia are found in men with liver disease, neither of these factors can provide a satisfactory explanation for the development of gynaecomastia in this condition. Progesterone may, however, be an additional agent acting with the modest hyperoestrogenaemia and reduced circulating androgen'9 2() disturbances that at present appear to be the more important abnormalities associated with gynaecomastia.
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